SCHEMBL5776483

SCHEMBL5776483

N/N=C(/c1ccc(-c2cnco2)cc1)c1ccc(S(N)(=O)=O)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK1 P06493 3/20 0.49
CDK2 P24941 3/20 0.49
CCNA2 P20248 1/20 0.49
KMT2A Q03164 2/20 0.44
POLB P06746 1/20 0.44
PKM P14618 3/20 0.43
LMNA P02545 2/20 0.43
NOTUM Q6P988 1/20 0.43
GAA P10253 1/20 0.43
CA2 P00918 5/20 0.43
CA9 Q16790 5/20 0.43
CA12 O43570 4/20 0.43
CA1 P00915 4/20 0.43
KDM4E B2RXH2 2/20 0.42
NPC1 O15118 2/20 0.42
CA14 Q9ULX7 2/20 0.42
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
PSEN1 P49768 1/20 0.41
PSEN2 P49810 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3095961 0.87 NOTUM (0.55) CDK1CDK2CCNA2KMT2APOLB
SCHEMBL5775952 0.83 NPC1 (0.49) KMT2APOLBPKMLMNANOTUM
SCHEMBL5779456 0.79 GPR119 (0.45) KMT2APKMLMNANOTUMGAA
SCHEMBL5777062 0.78 NPC1 (0.44) KMT2APOLBPKMLMNANOTUM
SCHEMBL5777821 0.78 NPC1 (0.42) CDK1CDK2CCNA2KMT2APOLB
SCHEMBL5778725 0.75 KDM4E (0.48) KMT2APOLBPKMLMNACA2
SCHEMBL13836472 0.75 PKM (0.55) KMT2APOLBPKMLMNANOTUM
SCHEMBL343986 0.73 NOTUM (0.61) KMT2APOLBPKMLMNANOTUM
SCHEMBL5776487 0.73 KMT2A (0.62) CDK1CDK2KMT2APOLBLMNA
SCHEMBL9026241 0.71 LMNA (0.59) KMT2APOLBPKMLMNANOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060276433-A1 Hydrazone derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-12-07 US disclosed
EP-1612204-A1 HYDRAZONE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-01-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276433-A1 Hydrazone derivative APP, PRNP, HTT CDK1 2587/4885CDK2 2424/4885CCNA2 2429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.